Low-Dose Aspirin In The Prevention Of Pre-Eclampsia With Potential Bleeding Risk Undergoing Treatment In Tertiary Care Hospital
Keywords:
Aspirin, Postpartum hemorrhage, Body mass index, Pre-eclampsiaAbstract
The present research is assessing the potential of low-dose aspirin as a preventative measure for pre-eclampsia. The incidence of postpartum hemorrhage (PPH) did not change statistically significantly between the aspirin and control groups. The purpose of this study was to assess the possible bleeding risk of 100 mg aspirin in high-risk pregnant women (62) as well as the variation in PPH incidence based on maternal factors. At five follow-up visits, coagulation test results and platelet counts were gathered. The study examined subgroups based on mother age (less than 35 years and more than 35 years), pre-pregnancy body mass index (pre-BMI, less than 28 kg/m² and more than 28 kg/m²), parity, gestational age at enrolment, and medical history, which included diabetes mellitus, chronic hypertension, and pre-eclampsia. To determine if there was a significant difference in the incidence of PPH following aspirin administration to pregnant women in each subgroup, logistic regression analysis was employed. Multiple logistic regression models were used to make changes after these findings. The aspirin and control groups did not vary significantly in terms of bleeding risk . When examining certain subgroups, there was no discernible difference in the overall incidence of PPH between the aspirin group and the control group. There was no significant correlation between pre-BMI and PPH in the control group, but there was in the aspirin group. Regardless of the mother's characteristics, a daily dose of 100 mg of aspirin, starting between weeks 12 and 20 and continuing until weeks 34, did not raise the risk of possible bleeding and PPH. There was a substantial positive connection between PPH and BMI in the aspirin group.
Downloads
References
Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet 2016;387:999–1011. doi: 10.1016/S0140-6736(15)00070-7.
Ghazanfarpour M, Sathyapalan T, Banach M, Jamialahmadi T, Sahebkar A. Prophylactic aspirin for preventing pre-eclampsia and its complications: an overview of meta-analyses. Drug Discov Today 2020;25:1487–1501. doi: 10.1016/j.drudis.2020.05.011.
Rana S, Lemoine E, Granger JP, Karumanchi SA. Pre-eclampsia: pathophysiology, challenges, and perspectives. Circ Res 2019;124:1094–1112. doi: 10.1161/CIRCRESAHA.118.313276.
CLASP: a randomised study of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (collaborative low-dose aspirin study inpregnancy) Collaborative Group. Lancet 1994;343:619–629. doi: 10.1016/S0140-6736(94)92633-6.
Hastie R, Tong S, Wikström A-K, Sandström A, Hesselman S, Bergman L. Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-basedcohortstudy. Am JObstet Gynecol 2021;224:95.e1–95.e12. doi: 10.1016/j.ajog.2020.07.023.
Sirico A, Saccone G, Maruotti GM, Grandone E, Sarno L, Berghella V, et al. Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2019;32:1893–1900. doi: 10.1080/14767058.2017.1419179.
Lin L, Huai J, Li B, Zhu Y, Juan J, Zhang M, et al. A randomized controlled study of low-dose aspirin for the prevention of preeclampsia in women at high risk in China. Am J Obstet Gynecol 2022;226:251.e1–251.e12. doi: 10.1016/j.ajog.2021.08.004.
Zhu J, Huang R, Zhang J, Ye W, Zhang J. A prophylactic low-dose aspirin earlier than 12 weeks until delivery should be considered to prevent pre-eclampsia. Med Hypotheses 2018;121:127–130. doi: 10.1016/j.mehy.2018.08.005.
Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013;30:260–279. doi: 10.3109/07420528.2012.717455.
Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin use to prevent preeclampsia and related morbidity and mortality: updated evidence report and systematic review for the US preventive services task force. JAMA 2021;326:1192–1206. doi: 10.1001/jama.2021.8551.
Man R, Hodgetts Morton V, Devani P, Morris RK. Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2021;262:105–112. doi: 10.1016/j. ejogrb.2021.05.017.
Ye Y, Wen L, Liu X, Wang L, Liu Y, Saffery R, et al. Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching. Bmc Pregnancy Childbirth 2021;21:786. doi: 10.1186/s12884-021-04217-2.
Mone F, Mulcahy C, McParland P, Breathnach F, Downey P, McCormack D, et al. Study of feasibility and acceptability of routine low-dose aspirin versus early screening test indicated aspirin for pre- eclampsia prevention (TEST study): amulticentre randomised controlled study. BMJ open 2018;8:e022056. doi: 10.1136/bmjopen-2018-022056.
Gu W, Lin J, Hou YY, Lin N, Song MF, Zeng WJ, et al. Effects of low-dose aspirin on the prevention of preeclampsia and pregnancy outcomes: a randomized controlled study from Shanghai, China. Eur J Obstet Gynecol Reprod Biol 2020;248:156–163. doi: 10.1016/j. ejogrb.2020.03.038.
Shan T, Wang P, Fang F. Effects of low-dose aspirin combined with vitamin E on the incidence of intrauterine growth restriction and hemorheological indexes of pregnant women in patients with gestational hypertension. Comput Math Methods Med 2022;2022:6328807. doi: 10.1155/2022/6328807.
Noever K, Schubert J, Reuschel E, Timmesfeld N, Arabin B. Changes in maternal body mass index, weight gain and outcome of singleton pregnancies from 2000 to 2015: a population-based retrospective cohort study in Hesse/Germany. Geburtshilfe Frauen- heilkd 2020;80:508–517. doi: 10.1055/a-1110-0859.
Thies-Lagergren L, Kvist LJ, Gottvall K, Jangsten E. A Swedish register-based study exploring primary postpartum hemorrhage in 405 936 full term vaginal births between 2005 and 2015. Eur J Obstet Gynecol Reprod Biol 2021;258:184–188. doi: 10.1016/j. ejogrb.2020.12.018.
Li S, Gao J, Liu J, Hu J, Chen X, He J, et al. Incidence and risk factors of postpartum hemorrhage in China: a multicenter retrospective study. Front Med (Lausanne) 2021;8:673500. doi: 10.3389/fmed.2021.673500.
Indarti J, Susilo SA, Hyawicaksono P, Berguna JSN, Tyagitha GA, Ikhsan M. Maternal and perinatal outcome of maternal obesity at RSCM in 2014-2019. Obstet Gynecol Int 2021;2021:6039565. doi: 10.1155/2021/6039565.
Butwick AJ, Abreo A, Bateman BT, Lee HC, El-Sayed YY, Stephansson O, et al. Effect of maternal body mass index on postpartum hemorrhage. Anesthesiology 2018;128:774–783. doi: 10.1097/Aln.0000000000002082.
Bjorklund J, Wiberg-Itzel E, Wallstrom T. Is there an increased risk of cesarean section in obese women after induction of labor? A retrospective cohort study. PLoS One 2022;17:e0263685. doi: 10.1371/journal.pone.0263685.
Erickson EN, Lee CTS, Carlson NS. Predicting postpartum hemorrhage after vaginal birth by labor phenotype. J Midwifery Womens Health 2020;65:609–620. doi: 10.1111/jmwh.13104.
Liu L, Wang H, Zhang Y, Niu J, Li Z, Tang R. Effect of pregravid obesity on perinatal outcomes in singleton pregnancies following in vitro fertilization and the weight-loss goals to reduce the risks of poor pregnancy outcomes: a retrospective cohort study. PLoS One 2020;15:e0227766. doi: 10.1371/journal.pone.0227766.
Ouh YT, Lee KM, Ahn KH, Hong SC, Oh MJ, Kim HJ, et al. Predicting peripartum blood transfusion: focusing on pre-pregnan- cy characteristics. BMC Pregnancy Childbirth 2019;19:477. doi: 10.1186/s12884-019-2646-3.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
